Francisco Hermida‐Prado

机构：Universidad de Oviedo, Instituto de Salud Carlos III, Medical Research Network, Instituto de Investigación Sanitaria del Principado de Asturias · ORCID：0000-0002-2916-0337

发表论文 158 篇 · 总被引 1022 次 · h-index 20

代表论文

• Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer (2025 · JCI Insight · 被引 13)
• Tamoxifen induces PI3K activation in uterine cancer (2025 · Nature Genetics · 被引 7)
• CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer (2025 · Signal Transduction and Targeted Therapy · 被引 6)
• IFN-γ signaling drives multiple immunosuppressive pathways and poor clinical outcome in glioblastoma (2026 · BMC Medicine)
• Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512] (2026 · Biomedicine & Pharmacotherapy)
• Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer (2025)